Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

<< Previous

Bullboard Posts

Next >>

Post by losingmyshirton Nov 26, 2021 9:15am

241 Views

Post# 34168168

Time to warm up the tar and find some feathers

Oh Bob, What do you do now? GVHD never went anywhere after all of the hype that you spread.
Looking like R107 will not be the buzz word does it.
By the looks of things you might have to announce that things will look better on 2025 when Kaly is expected to release their new R107 infused socks that can be worn while swimming.

All in all you had a good run and did manage to keep your paycheques coming. Remarkable how many people pumped money into this pipe dream. No office, no employees, nothing of substance.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing